CAJ | 학술논문

目的：探讨奥沙利铂（OXA）联合替吉奥胶囊一线治疗晚期食管癌的疗效及不良反应。方法将35例采用OXA联合替吉奥胶囊（SOX方案）化疗的晚期食管癌患者设为治疗组，32例行顺铂（DDP）联合氟尿嘧啶（DF方案）化疗的患者设为对照组。观察及随访两组患者的近、远期疗效及不良反应。结果治疗组及对照组的近期有效率分别为62.9%和37.5%，比较有统计学差异（P＜0.05），疾病控制率分别为85.7%和65.6%，组间比较无统计学差异（P＞0.05）。治疗组的中位生存期（12.4个月）与对照组（10.4个月）相比有统计学差异（P＜0.05），两组患者1年生存率分别为54.3%和34.4%，2年生存率分别为5.7%和0.0%，两组间均无统计学差异（χ2=2.680、2.654，均P＞0.05）。在不良反应方面，两组患者的血液学、消化道不良反应及肝功能损害比较无统计学差异（均P＞0.05），治疗组神经系统不良反应发生率高于对照组（P＜0.05）。结论 OXA联合替吉奥（SOX方案）治疗晚期食管癌疗效较为肯定，患者耐受良好。
목적：탐토오사리박（OXA）연합체길오효낭일선치료만기식관암적료효급불량반응。방법장35례채용OXA연합체길오효낭（SOX방안）화료적만기식관암환자설위치료조，32례행순박（DDP）연합불뇨밀정（DF방안）화료적환자설위대조조。관찰급수방량조환자적근、원기료효급불량반응。결과치료조급대조조적근기유효솔분별위62.9%화37.5%，비교유통계학차이（P＜0.05），질병공제솔분별위85.7%화65.6%，조간비교무통계학차이（P＞0.05）。치료조적중위생존기（12.4개월）여대조조（10.4개월）상비유통계학차이（P＜0.05），량조환자1년생존솔분별위54.3%화34.4%，2년생존솔분별위5.7%화0.0%，량조간균무통계학차이（χ2=2.680、2.654，균P＞0.05）。재불량반응방면，량조환자적혈액학、소화도불량반응급간공능손해비교무통계학차이（균P＞0.05），치료조신경계통불량반응발생솔고우대조조（P＜0.05）。결론 OXA연합체길오（SOX방안）치료만기식관암료효교위긍정，환자내수량호。
Objective To investigate the efficacy of oxaliplatin combined with S- 1 capsule (Tegafur, Gimeracil and Oteracil Potassium Capsules) as first- line therapy for patient with advanced esophageal cancer. Methods Sixty seven pa-tients with advanced esophageal cancer were treated with two different regimes:35 patients receiving SOX (oxaliplatin plus S- 1 capsule) as study group, and 32 patients receiving DF(cisplatin plus fluorouracil) as control group. The short- term, long- term ef-ficacy and adverse reactions were observed and compared between two groups. Results The short- term effective rate of study group was higher than that of control group (62.9%vs 37.5%, P<0.05), and there was no significant difference in disease control rate between two groups (85.7% vs 65.6%, P>0.05). The median survival time of study group was longer than that of control group (12.4 months vs 10.4 months, P<0.05). The 1- y survival rates were 54.3%and 34.4%, 2- y survival rates were 5.7%and 0.0% in two groups, respectively (χ2=2.680, 2.654, both P >0.05). There were no significant differences in the toxicity of hematopoietic system, gastrointestinal system and liver(P>0.05);the neurotoxicity incidence of SOX regime was higher than that of DF regime (P<0.05). Conclusion Oxaliplatin combined with S- 1 capsule is an effective and wel- tolerated chemotherapy regime for advanced esophageal cancer.